This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
GARDEN CITY, N.Y.,
May 2, 2013 /PRNewswire/ --
Millennium HealthCare Inc. (OTC Pink: MHCC) today announced that its Medical Device subsidiary signed an agreement with Atossa Genetics Inc. (NASDAQ: ATOS) for the distribution of Atossa's ForeCYTE Breast Health devices, which consist of the patented MASCT pump and ForeCYTE patient collection kits. Millennium has submitted an initial order for 10,000 ForeCYTE collection kits, which it intends to market to managed-care networks, healthcare clinics and physician practices in the
New York Metro Area and
Northern New Jersey.
Atossa's MASCT system is used by physicians and nurses to collect a small amount of nipple aspirate fluid for analysis by the National Reference Laboratory for Breast Health with the ForeCYTE Breast Health Test.
The ForeCYTE test, intended for the 110 million women in the U.S. ages 18-73, is a painless, quick and non-invasive procedure that can be performed in a physician's office. ForeCYTE can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight-year period before cancer can be detected by mammography or other means. Millennium HealthCare, through its wholly-owned operating subsidiaries, provides primary care physicians practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection.
Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "We are extremely pleased that Millennium HealthCare will be distributing the ForeCYTE Breast Health devices to its healthcare practitioners. Millennium shares our passion about providing life-saving diagnostics to its healthcare professionals and we look forward to working closely with the Millennium team."
Chris Amandola, President of Millennium HealthCare, stated, "According to a recent American Cancer Society report, there were over 200,000 new cases of invasive breast cancer among women in 2012. Excluding cancers of the skin, breast cancer is the most common cancer among women, accounting for nearly 1 in 3 cancers diagnosed in U.S.
With over 38 million mammography procedures performed over the past year, our distribution channels are very excited by the prospect that Atossa's non-invasive test can offer physicians a simple and cost-effective preventive care solution to their patients for the early detection of precursors to breast cancer."